Top Markets
#1 Pleasing Gold Pleasing Gold +1,557.08%
#2 PulseChain PulseChain +55.72%
#3 DogBull DogBull +37.22%
#4 Ontology Gas Ontology Gas +35.76%
#5 BOOK OF MEME BOOK OF MEME +31.40%
#6 Collect on Fanable Collect on Fanable +24.33%
#7 Neiro Neiro +20.73%
#8 Pump.fun Pump.fun +18.66%
#9 Unit Pump Unit Pump +18.66%
#10 Cryptopia Cryptopia +17.74%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
Rank in Stocks #26781
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Share Price
$0.52468396
Market Cap
$37.85M
Change (1 day)
1.23%
Change (1 year)
-4.53%
Country
TW
Trade Enimmune corporation (6564)

Category

Healthcare
Revenue for Enimmune corporation (6564)
Revenue in Aug 2026 TTM: 0
According to Enimmune corporation latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Enimmune corporation from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH